| ID | 1279 |
| Name of the vaccine | Eupenta Inj. |
| Microbe | Bacteria |
| Disease name | Pertussis (Whooping Cough) |
| Name of bacteria | Bordetella pertussis |
| Type of vaccine | Conjugate |
| Nucleic acid content | DNA |
| Age | 6 to 8 weeks |
| Description of the vaccine | Fully liquid pentavalent vaccine. |
| Name of the manufacturer | LG Chem |
| Name of the manufacturing country | NA |
| Year of manufacture | 2020 |
| Clinical Phase status | Clinical - Phase 4 |
| Bacterial strain | Gram-negative coccobacillus. |
| Efficacy | NA |
| Vaccine formulation | Liquid |
| Dosage | Three doses of 0.5 mL at 6, 10 and 14 weeks. |
| Mechanism of action | NA |
| Route of administration | NA |
| Indications | NA |
| Export | NA |
| Approval | NA |
| Adjuvant | NA |
| Repurposing | For diphtheria, tetanus, hepatitis B and haemophilus influenzae type b. |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | Combination (3 doses) |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NCT04056728 |
| Reference | NA |
| Other name | NA |
| Additional Links | NA
|